Posted by Michael Wonder on 04 Feb 2021
Thousands of lung cancer patients to benefit from life extending treatment
4 February 2021 - A potentially life extending treatment for some people with non-squamous, non-small-cell lung cancer will now be available on the NHS following its approval by NICE in draft guidance published today.
The draft guidance means pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy will be available as a first-line treatment option for adults whose tumours have no epidermal growth factor receptor positive or anaplastic lymphoma kinase positive mutations.
